MedTrace Logo

Sacral Neuromodulation for Chronic Pelvic Pain

NCT06150599 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-12-11

No results posted yet for this study

Summary

Sacral neuromodulation (SNM) is a safe, effective, and minimally invasive FDA approved treatment for urinary and fecal incontinence, urinary frequency, urgency, and urinary retention. In this study we are assessing the effectiveness of sacral neuromodulation in women with suffering from chronic pelvic pain (CPP), through a single device implant procedure.

Conditions

  • Chronic Pelvic Pain Syndrome

Interventions

DEVICE

Sacral neuromodulation

Interstim X, which includes an implantable pulse generator and lead, will be implanted surgically in a single-stage procedure.

Sponsors & Collaborators

  • Corewell Health East

    lead OTHER

Principal Investigators

  • Kenneth Peters, MD · Corewell Health William Beaumont University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
22 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2028-04-01
Completion
2028-12-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06150599 on ClinicalTrials.gov